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Introduction
Urothelial bladder cancer (UBC) constitutes the fourth and ninth most common cancer in the Western world in men and women, respectively (1) . This high prevalence and the relapsing nature of UBC pose this cancer as an enormous burden on health-care systems (2) . Approximately 75% of newly diagnosed UBCs are non-muscle-invasive (NMI) with a high rate of recurrence and progression despite local therapy. The remaining 25% of UBCs are muscle invasive: patients affected need either radical surgery or radiotherapy but often still have poor outcomes despite systemic therapy (1) .
The high rates of recurrences and the inaccuracy of standard detection procedures highlight the need for most efficient and less invasive technologies for UBC surveillance (2) . An essential aspect of prevention of UBC recurrence is an extensive and long-term follow-up. For example, cystoscopy is currently performed every 3-6 months (according to the disease risk classification tables) for at least the initial 2 years in patients with UBC (3). The procedure is costly for the health system and it is frequently associated with discomfort and urinary tract infections. Development of new non-invasive and clinically informative biomarkers could significantly improve the management of patients with UBC (4) .
Several UBC tissue gene profiles have been reported predicting a range of tumor characteristics and outcomes (5) . However, to improve accuracy and overcome the disadvantages of current diagnostic strategies, the detection of UBC biomarkers in body fluids rather than tissues taken with biopsies could result in a more promising approach (6) .
The search for cancer biomarkers in blood or urine offers several advantages over target tissue samples, such as minimal invasiveness, potential for continuous measurements and relatively high tissue homogeneity. Various blood biomarkers have been investigated for cancer; among them the matrix metalloproteinases (MMPs) have been identified as potential body fluids biomarkers in UBC (5) . The MMP family is composed of enzymes with the capacity to degrade the components of extracellular matrix (6) . Although not generally used as a cancer diagnostic marker, MMP expression has been widely studied as a potential prognostic marker for a number of malignancies (7) .
In this study, we performed genome-wide gene expression analyses and subsequent validation by qPCR in peripheral blood mononuclear cells (PBMCs) of 66 patients with UBC and 70 controls. We observed a downregulation of MMP23B gene and its pseudogene MMP23A in UBC when compared with controls. This finding encouraged us to also evaluate MMP23B protein levels, both in plasma and in urine samples, and to investigate the presence of microRNAs (miRNAs) targeting the MMP23B gene in urine of patients with UBC and controls.
Materials and methods

Study design and patients
The study population included all men newly diagnosed and histologically confirmed as UBC cases who registered at two urology departments of AOU Città della Salute e della Scienza, in Turin (Italy), during the years 1994-2012. All subjects, aged 40-75 years, were living in the Turin metropolitan area and were enrolled for a large hospital-based study on UBC: the Turin Bladder Cancer Study (8, 9) . Before any treatment, a trained interviewer used a detailed questionnaire to conduct a face-to-face interview to obtain information on demographics and cancer risk factors. Men were recruited in a daily random fashion as controls from patients treated at the same urology departments for non-neoplastic diseases or from patients treated at the medical and surgical departments for other benign diseases. Patients with cancer, liver or renal diseases, as well as smokingrelated conditions, were excluded. All subjects were informed and provided written consent to participate in the study and approved the use of their biological samples for the analyses, according to the Helsinki declaration. This study was approved by the Institutional Review Boards of the Human Genetics Foundation (since January 2017 named Italian Institute for Genomic Medicine) and by the ethics committee of AOU Città della Salute e della Scienza Hospital.
Patients with UBC were followed with periodic cystoscopic examinations by urologists who also provided clinical information, including the type of therapies. Details of the study population were described previously in Pardini et al. (9) .
Information regarding UBC cases and controls are described in Table  I The overlap between samples used in all tests/assays performed in this study is presented in Supplementary Figure 1 , available at Carcinogenesis Online.
Sample collection
Blood and urine sampling were performed either at the time of diagnosis (for UBC cases) or at the time of recruitment (for controls). Samples were immediately processed after collection [PBMC isolation and storing as described in Turinetto et al. (8) , plasma separation as described in Ferrero et al. (10) , centrifugation of urine with separation of urine exfoliated cells as described in Ferrero et al. (10) ]. For all subjects, plasma was obtained from 5-8 ml of ethylenediaminetetraacetic acid blood centrifuged for 10 min at 1000 r.p.m.. Plasma aliquots (about 200-300 μl each) were then stored at −80°C until use (minimum 4-5 years after collection). Urine samples were collected in the morning, stored at 4°C until the processing consisting of centrifugation at 3000g for 10 min. The urine supernatant aliquots were then transferred in tubes and stored at −80°C until use (minimum 4-5 years after collection).
RNA isolation (gene expression and small RNA-seq)
Total RNA was extracted from cryopreserved PBMCs from UBC cases (collected before any treatment) and controls (8, 9) . Total RNA was isolated using RNeasy extraction kit (Qiagen) following the manufacturer's protocol. The integrity of purified RNA was assessed using the RNA 6000 Nano Kit on an Agilent 2100 Bioanalyzer (Agilent Technologies) and RNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies).
Samples from UBC cases and controls were selected according to the following quality control requirements: RNA Integrity Number ≥7, at least 300 ng RNA available.
Total RNA from urine was extracted with Urine microRNA Purification kit (Norgen Biotek Corp), following the manufacturer's standard protocol. RNA quality and quantity was verified according to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments guidelines (http://miqe.gene-quantification.info/). For all urine samples, RNA concentration was quantified by Qubit® 2.0 Fluorometer with Qubit® microRNA Assay Kit (Invitrogen).
Gene expression microarray
RNA from PBMCs was amplified, biotin-labeled and hybridized on the Illumina Human BeadChip HT12 v4 whole genome expression array (66 UBC cases and 70 controls, Discovery set, Table 1 ). The Human HT-12 v4 BeadChip is a genome-wide gene expression array that targets >31 000 annotated transcripts with >47 000 probes derived from the National Center for Biotechnology Information Reference Sequence. All arrays were performed by the same operators in the same core facility. Synthesis of doublestranded complementary DNA (cDNA), preparation and labeling of cRNA, hybridization to HumanHT-12 v4 BeadChip (Illumina, San Diego, CA), washing and scanning were performed according to Illumina standard protocols. Slides were scanned using Illumina HiScan and the signal was analyzed and extracted using GenomeStudio software (Illumina, San Diego, CA).
Abbreviations
ABL1
Abelson The Abelson murine leukemia viral oncogene homolog 1 (ABL1;Hs00245443_ m1) and hypoxanthine phosphoribosyltransferase 1 (HPRT1; Hs02800695_m1) genes were used as reference genes for qPCR normalization. These reference genes are among the most stably expressed in PBMCs, suitable for normalization in qPCR studies (http://www.genecards.org/). Moreover, they were identified by Applied Biosystems as appropriate for expression levels normalization in PBMCs. QPCR was performed in a 7900HT Real-Time PCR System (Applied Biosystems). Each sample was run in triplicate.
Replication in an independent set of samples
The same genes subject to the technical validation were further investigated in an independent set of samples (21 patients with UBC and 24 controls, Replication set, Table 1 ). The qPCR methodology was applied as described earlier. TCGA RNA-seq data were generated with Illumina HiSeq RNAseq, summarized by exons and genes and presented as log2-transformed reads per kilobase million values for each exon in two separate panels for a subset of normal and tumor tissue samples (12) . In total, RNA-seq data from 267 UBC tissues and 19 adjacent non-malignant urothelial tissue samples were included as external validation.
Library preparation for small RNA-seq
The complete description of small RNA-seq experiments is described in Supplementary Materials, available at Carcinogenesis Online (13 
Western blot analysis
Twenty microliters of plasma (diluted 1:500) or urine supernatants were boiled at 99°C for 10 min in a reducing Laemmli sample buffer (Bio-Rad, Segrate, Italy), resolved as proteins by SDS-PAGE Mini-PROTEAN TGX Stain-Free Precast Gels 10% (Bio-Rad), and transferred to Mini format 0.2 um nitrocellulose membranes (Trans-Blot Turbo Transfer System, Bio-Rad). Blots were incubated overnight with anti-MMP23B antibody 1:500 (Abcam, ab155416) and subsequently with a mouse anti-rabbit IgG-HRP conjugate antibody 1:2000 (Santa Cruz Biotechnology, sc-2357) for 1 h. Blots were developed by using enhanced chemiluminescence (Clarity Western ECL Blotting Substrate, Bio-Rad). Image acquisition was performed using ImageQuant LAS4000 and TL Version 7.0 software (GE Healthcare, Milan, Italy).
Enzyme-linked immunosorbent assays
The level of human MMP23B protein was quantified blinded in plasma and urine samples using enzyme-linked immunosorbent assay (ELISA) kit (Cat# MBS2516225, MyBiosource, San Diego, California). The assay was conducted according to the manufacturer's instructions. Curve fitting was accomplished by either linear or four-parameter logistic regression following manufacturer's instructions. The relatively constant production of creatinine, a non-enzymatic metabolite of creatine, makes urinary creatinine a useful tool for normalizing the levels of other molecules found in urine (14) . The concentration of urinary creatinine was measured using a commercially available enzymatic assay (Cat# KGE005 R&D Systems, Minneapolis, MN) according to the manufacturer's instruction. The measured creatinine concentrations in urine were added in a generalized linear regression model to adjust statistical analyses on urinary MMP23B differences between UBC cases and controls. Creatinine levels between cases and controls were not significantly different (mean UBC = 114.02 mg/dl; mean controls = 100.80 mg/dl; adjusted linear regression P = 0.09).
Statistical analyses
Raw data obtained from the Illumina Human HT12 arrays were checked with Lumi, which performed the quality control, variance stabilization and normalization of the dataset. Expression values were log2 transformed.
Differential expression analysis (all patients or only NMI cases versus controls) was performed using Limma (lmFit and ebayes functions). The up-or downregulated genes associated with a Benjamini-Hochberg false discovery rate (FDR) P-value <0.05 were considered for further analysis.
For qPCR analyses (technical validation and replication in an independent set of samples), relative expression values were normalized to the reference genes (HPRT1 and ABL1), and fold change values were calculated by using the 2-ΔΔCt method. Student's t or Wilcoxon rank sum tests were used (depending on Shapiro-Wilk normality test results) to compare the ΔCt values between the two biological groups (UBC versus controls), and a P-value was calculated.
Same tests were used to compare the distribution of MMP23A/MMP23B gene expression levels or MMP23B protein measurements in plasma and urine between groups. Multivariate analyses were adjusted for age and smoking (and creatinine levels only for urine).
Overall survival was evaluated calculating the time (in years) between the date of UBC diagnosis and the date of death or follow-up termination as the endpoint for each patient. Event-free survival was calculated as the time (in years) between the date of UBC diagnosis until date of relapse, death or censorship, whichever came first. The relative risk of death or recurrence against urinary MMP23B was estimated as hazard ratios using Cox regression (R Survival package).
Small RNA-seq data analysis was performed as described in Supplementary Materials, available at Carcinogenesis Online.
To identify miRNAs targeting the MMP23B gene, we used miRWalk 2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/), a complete atlas of predicted and validated miRNA-target interactions. MiRWalk shows miRNA-targets interaction information produced also by other established miRNA prediction programs; between them we chose RNA22 (https:// cm.jefferson.edu/rna22/), miRanda (15) and TargetScan (http://www.targetscan.org/vert_71/). We selected those miRNAs predicted to target MMP23B by at least three of the used tools. We conducted differential expression analysis among UBC cases and controls with DESeq2 Bioconductor package. Over/under expression was evaluated with Wald test and results were given as log2 fold changes for UBC cases over controls. MiRNAs were considered significantly differentially expressed when FDR P-value <0.05.
All the analyses were performed with the open source R (version 3.2.4).
Results
Discovery set: gene expression microarray analysis
RNA samples from PBMCs of 66 UBC cases and 70 controls were included in the Discovery set and analyzed with a whole genome expression array (Table 1) . Overall, 20 096 genes were detected. The genes differentially expressed among UBC and controls (adj P-value <0.05) are reported in Supplementary Table 2, available at Carcinogenesis Online and in Figure 1A . Similar analyses were conducted selecting NMI UBC samples versus controls ( Figure 1B 
There was a significant decreased expression of the MMP23B gene and its relative pseudogene MMP23A in UBC cases compared with controls (log FC = −0.37, FDR adj P-value = 0.02 and log FC = −0.23, FDR adj P-value = 0.03, respectively, adjusted for age, smoking and experimental batch). These differences also arose when only NMI UBC were analyzed (MMP23B log FC = −0.39, FDR adj P-value = 0.02; MMP23A log FC = −0.24, FDR adj P-value = 0.04; adjusted for age, smoking and experimental batch).
MMP23A and MMP23B are highly homologous. Alignment (Basic Local Alignment Search Tool, BLAST) of ILMN_2193325 and ILMN_1790052 probes showed that they failed to be specific. Therefore, despite Illumina indication, probes could not distinguish between the two genes.
Validation and replication of MMP23A and MMP23B gene expression by qPCR
The differential expression levels of MMP23A and MMP23B genes were confirmed in the Validation set (44 UBC cases and 57 controls) by qPCR. Also in this case, despite TaqMan probe manufacturer's indications, the positions recognized by Hs00270380_m1 and Hs04187882_g1 probes fail to be specific and could not recognize between MMP23A and MMP23B.
Specifically, for both assays there was a significant downregulation of the gene in UBC cases versus controls (MMP23 Hs00270380_m1 probe: t test P = 0.014; adj P-value = 0.02; MMP23 Hs04187882_g1 probe: Wilcoxon P-value = 0.005; adj P-value = 0.012; adjusted for age and smoking, Figure 2A and B). In the Replication set (21 UBC and 24 controls), trends were similar but not statistically significant (MMP23 Hs00270380_m1 probe: t test P = 0.73; adj P-value = 0.81; MMP23 Hs04187882_g1 probe: t test P-value = 0.30; adj P-value = 0.29; adjusted for age and smoking, Figure 2C , rho = 0.959). When the analysis was performed on all cases and controls (Validation + Replication sets, n = 146, 65 UBC and 81 controls), we observed a significant downregulation of genes in cases compared with controls (MMP23 Hs00270380_m1 probe: Wilcoxon P-value = 0.037; adj P-value = 0.15; MMP23 Hs04187882_g1 probe: Wilcoxon P-value = 0.006; adj P-value = 0.03; adjusted for age and smoking; data not shown).
MMP23A and MMP23B gene expression validation on TCGA
The TCGA dataset available on Wanderer tool consists of 267 muscle-invasive UBC tissues and 19 adjacent non-malignant urothelial mucosa.
For all MMP23B-and MMP23A-detected transcripts, there was a significant downregulation in the tumor tissues compared with normal mucosa (Supplementary Table 4 ; data not shown), being MMP23A not expressed in the majority of samples.
MMP23B protein detection by western blot
The significant difference in MMP23B gene expression was further analyzed as protein expression by western blot analysis both in plasma and urine samples in nine UBC cases and nine controls. The aim was to evaluate if MMP23B was secreted in these biofluids, because this piece of information is still lacking. Interestingly, we observed the presence of MMP23B protein in both biofluids, in both groups, with a molecular weight of about 50 kDa ( Figure 3A ). As we did not perform a quantitative western blot, we could not speculate on differences between cases and controls. However, the amount of protein in plasma was higher than in urine, as plasma samples were diluted 1:500, whereas urine samples were run undiluted.
MMP23B protein quantification by ELISA assay in plasma and urine
We quantified MMP23B protein levels in plasma (49 controls and 53 UBC) and urine (57 controls and 59 UBC) samples from the same study (description of subjects in Supplementary Table 1, available at Carcinogenesis Online). MMP23B levels were higher in cases respect to controls, both in plasma and in urine, with the difference statistically significant only in urine (plasma: mean UBC = 697.60 ng/ml, mean controls = 543.80 ng/ml, P-value = 0.17; urine: mean UBC = 1797.70 pg/ml, mean controls = 1075.73 pg/ ml, P-value = 0.02, Figure 3B ). Similar results, although not statistically significant, were obtained comparing controls with NMI UBC (plasma: mean NMI = 701.32 ng/ml, mean controls = 543.80 ng/ml, P-value = 0.19; urine: mean NMI = 1637.54 pg/ml, mean controls = 1075.73 pg/ml, P-value = 0.06; data not shown). MMP23B levels were higher in plasma than in urine, as already visualized by western blot experiments.
The correlation between plasma and urine measurements was not significant (n = 42, Spearman correlation P-value = 0.29, rho = 0.167; data not shown). When we performed a general logistic regression analysis adjusting for smoking habits and age (and for creatinine levels for urine), we obtained significant differences between cases and controls in urine samples, both analyzing all cases and NMI UBC only (all UBC P-value = 0.02; NMI P-value = 0.01; data not shown).
MMP23B protein levels in plasma or urine were not connected with overall survival and event-free survival status of the studied group (data not shown).
Plasma MMP23B protein levels were not correlated with tumor clinical characteristics. On the other hand, urinary MMP23B levels in cases were significantly different across tumor grading [all UBC: World Health Organization (WHO) 1973 G3vsG1 adj linear regression P-value <0.0001; G2 versus G1 P-value = 0.02, Figure 4A ; WHO 2004/2016 adj linear regression P-value = 0.03, Figure 4B ; NMI: WHO 1973 G3vsG1 adj linear regression P-value <0.0001; G2vsG1 P-value = 0.02; WHO 2004/2016 adj linear regression P-value = 0.17; data not shown]. We also observed a significant positive trend between urinary MMP23B levels and tumor grading (WHO 1973 trend test, all UBC: P-value <0.0001; NMI: P-value <0.0001). Finally, urinary MMP23B levels were also significantly different between risk stratification classes (all UBC: high-versus low-risk adj linear regression P-value = 0.0009, Figure 4C ; NMI: high-versus lowrisk adj linear regression P-value = 0.001; data not shown), with a significant positive trend in all UBC and NMI UBC (trend test UBC: P-value <0.0001; NMI: P-value = 0.001).
Analysis of urinary miRNAs targeting MMP23B gene
We investigated urinary miRNA profiles in association with UBC and different clinic-pathological subtypes by small RNA-seq (Supplementary Materials, available at Carcinogenesis Online). In total, 114 urine samples (66 UBC and 48 controls) were sequenced. Among cases, 39 were G1 + G2 and 17, G3. The analysis of the raw reads has led to the definition of the starting count matrix composed of 114 samples and 2560 miRNAs, of which 343 were significantly differentially expressed (i.e. FDR P-value <0.05) among UBC and controls.
We retrieved all miRNAs targeting MMP23B and MMP23A in miRWalk 2.0. We found only predicted miRNAs targeting MMP23B (not MMP23A) in the canonical binding site on 3′untranslated regions (UTR) of the gene, but also on 5′UTR and on gene promoter. We focused only on those miRNAs that were predicted in at least three tools out of four (miRWalk 2.0, miRanda, RNA22, TargetScan). We obtained a list of 31, 8 and 330 predicted miRNAs binding sites in the 3′UTR, 5′UTR and gene promoter, respectively (Supplementary Table 5 , available at Carcinogenesis Online). Among those miRNAs differentially expressed in urine by small RNA-Seq, we found that five miRNAs targeting MMP23B 3′UTR were upregulated in UBC cases (miR-93-5p, miR-106b-5p, miR20a-5p, miR-17-5p and miR-3934-5p). Interestingly, 39 miRNAs targeting MMP23B in the promoter region resulted downregulated in the urine of cases compared with controls and miR34a-5p, in particular, was also targeting the gene in the 5′UTR region ( Table 2 ).
Discussion
In this study, we report altered MMP23B expression levels in PBMCs of patients with UBC compared with controls. The present outcomes indicate a potential role of MMP23B as possible non-invasive UBC biomarker. We also analyzed MMP23B protein levels in plasma and urine and found significantly higher levels in urine from cases in respect to controls. Moreover, urinary MMP23B levels were correlated with tumor risk and grade. These results are of particular importance as (i) they are relevant in the field of non-invasive biomarker detection of diagnosis for UBC; (ii) they add information on MMP23B characterization in UBC and (iii) they demonstrate the differential secretion of MMP23B protein in both plasma and urine of patients with UBC.
The identification of a biomarker for UBC screening and early diagnosis has primary importance in improving survival and patients' quality of life. Urine cytology is currently the most commonly used non-invasive test for UBC detection (3) . However, this test is of limited value owing to its poor sensitivity, especially for low-grade lesions (16) . Cystoscopy-guided biopsy for histological evaluation can offer high diagnostic accuracy, but it is invasive and inconvenient for patients, limiting its use in general cancer screening. UBC is among the most expensive cancers and poses a significant economic and social challenge because the high rate of recurrence necessitates continuous cystoscopic surveillance (17) . Hence, non-invasive and more sensitive molecular biomarkers are needed to improve current strategies for UBC detection and monitoring (16) .
Initially, we performed a whole-genome expression analysis in PBMCs and we identified altered levels of MMP23A and MMP23B genes between cases and controls as unique significant signal. We have tested gene expression in blood cells with the aim to find non-invasive UBC biomarkers, because previous studies reporting gene expression profiling in UBC were all performed on cancer tissue (18, 19) .
The two MMP23 genes, referred to as MMP23A (pseudogene) and MMP23B, generate three alternatively spliced products each (20) . Unfortunately, due to the high homology between MMP23A and MMP23B, both microarray and qPCR probes used in this study could not distinguish specifically between the two species. MMP23B gene is implicated in 1p36 deletion syndrome as it is located in the critical region for large, late-closing anterior fontanel (20) .
MMP23B is a unique member of the MMP family with a distinctive domain architecture and function. It has an N-terminal signal anchor that targets it to the cell membrane, and it is a type II transmembrane MMP, also characterized by its unique cysteine array and immunoglobulin-like domains (21) . It is still unknown the physiological function of MMP23B although there is evidence on its possible role in various cellular processes including bone matrix resorption and bone remodeling (21) .
The full-length protein (MMP23B) was found predominantly in ER membranes and perinuclear in mammalian cells, and it co-localizes with Kv1.3 potassium channel (22) . The observed specificity suggests that the protein may play a role in regulating Kv1 channel activity that is abnormal in cancer cells and have been identified as potential target for the treatment of various tumors (23) .
We took advantage of the large amount data for the molecular characterization of many tumor types, including UBC, provided by TCGA (12, 24) and we found that an MMP23B-decreased expression was confirmed in UBC tumor tissue. However, the TCGA cohort includes only patients with muscle-invasive tumor, whereas our study population was mostly represented by patients with NMI UBC (>80%). A previous study on tumor prostate tissue reported similar outcomes (25) , highlighting how prostate cancer shares a common carcinogenic process with UBC (26).
Because no additional aliquots of cryopreserved PBMCs were available, the measurement of MMP23B protein levels in blood cells was unfortunately not possible. As a consequence, we tested the presence of the protein in body fluids (plasma and urine) of patients with UBC and controls from the same cohort. We observed an increase of MMP23B in cases respect to controls, although the differences were statistically significant only in urine. Interestingly, a significant trend of MMP23 dosage was observed in UBC urine samples in relation to the tumor risk stratification or grading.
Increasing MMP23B protein levels in plasma and urine appear to contrast with the altered gene expression levels found in PBMCs. However, Vogel et al. (27) showed that the correlation between mRNAs and protein levels can be as little as 40% depending on the system. There are, in fact, many processes between transcription and translation that could affect correlation, among which protein stability regulation. The half-life of different proteins can vary from minutes to days whereas mRNA degradation rates would fall within a much tighter range (2-7 h for mammalian mRNAs versus 48 h for protein (27) ). Other important factors include the lower rate of mRNA transcription compared with protein translation in mammalian cells [two mRNAs transcribed per hour, on average versus dozens of proteins per mRNA per hour (27) ]. The lack of correlation between mRNA and protein levels could be due also to a posttranscriptional regulation mediated by miRNAs competing for both MMP23A and MMP23B genes.
Recently, it has been demonstrated that the interaction of the miRNA seed region with mRNA is not unidirectional. More specifically, the pool of mRNAs, transcribed pseudogenes and other non-coding RNAs compete for the same pool of miRNAs thereby regulating their activity (28) . These competitive endogenous RNAs act as molecular sponges for miRNAs through their miRNA response elements, thereby derepressing all target genes of the respective miRNA family (28) . To elucidate the possible miRNA/MMP23B cross talk, we searched for miRNAs targeting MMP23B by dedicated tools. We identified several candidate miRNAs with five of them differentially expressed in urine from UBC cases and controls. In particular, miR-93-5p, miR-106b-5p, miR-20a-5p, miR-17-5p and miR-3934-5p resulted upregulated in UBC. It is interesting to notice that miR-93-5p, miR-106b-5p and miR-17-5p have been associated previously with UBC, with miR-93-5p being upregulated both in tumor tissue and blood cells from patients with UBC, but not in urine (29) . On the other hand, miR-106b resulted upregulated in UBC preoperative cell-free urine compared with postoperative samples and its levels were associated with advanced tumor stage (30) . Finally, miR-17-5p was identified as one of the inflammasome-related miRNAs in UBC urine and was significantly upregulated in high-grade, high-risk and NMI-high-grade patients with UBC (31) .
The involvement of MMP23B in carcinogenesis was previously demonstrated for other tumors. Moogk et al. (32) showed an inverse association between primary melanoma, MMP23B protein expression in tumor tissue and the anti-tumor T-cell response, suggesting this protein as a new immunotherapeutic target. Although it has been observed that MMP23B promotes invasiveness in breast cancer cells (33) , to the best of our knowledge there is no other evidence of its role in the invasion of any cancer or even the detection in any cancer of altered levels of MMP23B in biofluids. The only study available by Chinello et al. (34) identified several peptides whose urinary levels varied according to tumor size, stage and grading of renal cell cancer. In particular, MMP23B urinary levels were lower in patients with renal cell cancer compared with controls and correlated negatively with tumor size, but increased in higher-grade tumors. In this study, we detected for the first time MMP23B protein in both plasma and urine of UBC. Pei et al. (35) have described a secreted MMP23B in the form of a fully processed mature glycosylated enzyme of 66 kDa, significantly larger than the intracellular form at 56 kDa. We observed a protein of 50 kDa reflecting more the previously observed intracellular form. Further biochemical analyses are necessary to better understand the physiological and pathological roles of MMP23B secreted forms.
Other MMPs have already been identified in urine or blood of patients with UBC (36) or in bladder tissues (37) . In particular, MMP7 and MMP9 have been detected in UBC urine as reliable prognostic biomarkers associated with advanced stage disease or poor survival (6, (38) (39) (40) (41) . MMPs, including MMP23B, could be used in combination with other biomarkers to increase accuracy. Patients with UBC need a constant, lifelong surveillance after diagnosis, thus MMPs could be used to allow the identification of patients at higher risk of recurrence (36) .
We are aware of some limitations of this study. First, we know that analytical performance of ELISA assay could be affected by urine complexity, which may hinder the efficient binding of a protein to its corresponding antibody used in the assay (42) . However, western blot data constitute a 'visual' correlation with ELISA quantification, giving us a certain confidence on the real levels of urinary MMP23B measured by ELISA assay.
Urine is of particular interest in UBC biomarker research, thanks to its direct contact with the tumor site and because it may contain high concentrations of tumor-derived proteins. Moreover, urine is an ideal biofluid because it can be easily and non-invasively collected at repeated intervals and in high quantities with no risk for donors. The major disadvantages of spot urine samples are the variation in dilution effects and in sample volume as well as urine production rate. In an attempt to adjust for this variation, urinary creatinine concentration is most commonly used in a ratio format to normalize analyte quantification for specimen concentration (43) . In this respect, we also adjusted for creatinine levels all the linear regression analyses performed on urinary MMP23B protein.
Conclusions
This study provides the first evidence on the presence of a secreted form of MMP23B in human biofluids (plasma and urine) and that urinary MMP23B levels might be a useful tool for UBC diagnosis. The functions of MMP23B and its expression regulation by miRNAs are intriguing both to understand new mechanisms in UBC onset and progression and to identify a group of urinary, non-invasive biomarkers useful to create a molecular profile of UBC at different stages and different risk to develop recurrences.
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